365462-23-3 Usage
Uses
Used in Pharmaceutical Research:
N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide is used as a research compound for exploring its potential interactions with biological targets due to its complex molecular structure and the presence of diverse functional groups.
Used in Drug Development:
In the pharmaceutical industry, N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide is utilized as a candidate molecule for the development of new drugs, leveraging its structural features to achieve therapeutic effects.
Further research and studies are essential to determine the specific properties, pharmacological activity, and potential therapeutic applications of N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide, as its exact uses and efficacy are yet to be fully understood and validated.
Check Digit Verification of cas no
The CAS Registry Mumber 365462-23-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,5,4,6 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 365462-23:
(8*3)+(7*6)+(6*5)+(5*4)+(4*6)+(3*2)+(2*2)+(1*3)=153
153 % 10 = 3
So 365462-23-3 is a valid CAS Registry Number.
365462-23-3Relevant academic research and scientific papers
Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor
Hirayama, Fukushi,Koshio, Hiroyuki,Ishihara, Tsukasa,Hachiya, Shunichiro,Sugasawa, Keizo,Koga, Yuji,Seki, Norio,Shiraki, Ryouta,Shigenaga, Takeshi,Iwatsuki, Yoshiyuki,Moritani, Yumiko,Mori, Kenichi,Kadokura, Takeshi,Kawasaki, Tomihisa,Matsumoto, Yuzo,Sakamoto, Shuichi,Tsukamoto, Shin-Ichi
, p. 8051 - 8065 (2012/03/08)
Inhibitors of factor Xa (FXa), a crucial serine protease in the coagulation cascade, have attracted a great deal of attention as a target for developing antithrombotic agents. We previously reported findings from our optimization study of a high-throughpu
